This article explores multiple methodologies for how to calculate a market size, including top-down and bottom-up approaches. [Read more…]
Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine.
It is clear that the stem cells contained within cord blood banking now have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 40,000 transplants worldwide.
Cord blood stem cells have distinct advantages over other sources, including that they are young, adaptable, and pure. These traits result from cord blood stem cells being the earliest (non-controversial) stem cells that can be extracted from a living human, and therefore, they haven’t been exposed to viruses, chemicals, or pollutants in the environment that can alter cell function.
While bone marrow stem cells are the most commonly recognized type of stem cell used in transplant, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant.
However, many expectant parents still do not fully understand the significance of cord blood storage or grasp the technical aspects that characterize it. This is also true of many investors who are evaluating opportunities for investing in the cord blood and tissue banking market.
With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.
However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.
Market Size, Segments, Storage Rates, Utilization, and Projections Through 2022
BioInformant, the first and only market research firm to specialize in the stem cell industry, announces the release of its “2018 Global Cord Blood Banking Industry Report.” The 265-page report reveals key forces affecting the industry, presenting trend rate data for cord blood and tissue clinical trials, patents, grants, and scientific publications. It reveals public and private storage counts for cord blood and tissue on a global basis, as well as market size metrics for the public and private sectors, with five-year projections through 2022. [Read more…]
The history of cord blood and tissue banking dates back to the early 1990’s when three private cord blood banks were formed within the United States. These banks were Cord Blood Registry, Cryo-Cell, and Viacord, all of which are AABB accredited banks. Shortly thereafter, cord blood banks began forming in leading healthcare markets worldwide.
In this article:
- Differences among Cord Blood Banks
- History of Cord Blood Storage
- History of Cord Tissue Storage
- Types of Perinatal Stem Cell Storage